McKesson Dives on Falling Earnings, Weak Guidance

One of the most contentious business issues in the 2016 presidential election campaign is the question of whether pharmaceuticals are too expensive Political rhetoric has spread into the wholesale pharmaceutical business and McKesson NYSE MCK has to be concerned that